Neuroimaging Core

神经影像核心

基本信息

批准号：
10666623
负责人：
SHANNON L RISACHER
金额：
$ 34.19万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-01 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10666623
关键词：
3-Dimensional Academia Aging Alzheimer&apos s Disease Alzheimer&apos s disease model Amyloid Award Biological Markers Brain imaging Cataloging Clinical Clinical Research Clinical assessments Collaborations Communities Data Data Set Degenerative Disorder Dementia Development Diffusion Discipline Disease Drug Industry Early Diagnosis Education Elderly Eligibility Determination Ensure Faculty Family Fostering Functional Magnetic Resonance Imaging Funding Genetic Genetic study Goals Grant Healthcare Human Hybrids Image Image Analysis Impaired cognition Indiana Individual Industry Inherited International Magnetic Resonance Imaging Measures Methodology Methods Molecular Mus Nerve Degeneration Neuropsychology Neurosciences Research Participant Pathologic Perfusion Phase Pilot Projects Positron-Emission Tomography Postdoctoral Fellow Productivity Protocols documentation Quality Control Research Research Personnel Resolution Resources Rest Rotation Sampling Scanning Schools Scientist Standardization Techniques Therapeutic Effect Therapeutic Studies Tracer Training Translational Research Validation Vision animal imaging arterial spin labeling causal variant cognitive testing connectome cooperative study data management design disease mechanisms study drug discovery education research experience genetic analysis imaging biomarker imaging genetics imaging modality improved in vivo metabolomics mild cognitive impairment multimodality neuroimaging neuropathology new therapeutic target outreach perfusion imaging pre-clinical prevent prisma programs protocol development recruit statistics symposium tau Proteins tau aggregation tool undergraduate student

项目摘要

Project Summary – Neuroimaging Core (NIC) The NIC of the IADRC will serve as a regional and national resource for the aging and neurodegeneration research community by providing access to, and collaborative support for, the application of advanced neuroimaging in clinical and translational research. The NIC has been productive in developing and implementing cutting-edge protocols and techniques in neuroimaging and imaging genetics analysis, collaborating with NIA-funded initiatives (e.g., ADNI, DIAN, ADGC, etc.), and in providing training in neuroimaging and imaging genetics to scientists of all levels and disciplines. In this application, the NIC will pursue the following specific aims: (1) Support funded research in the IADRC, IU Center for Aging Research, and related programs that currently employ or could benefit from advanced neuroimaging; (2) Provide standardized, state-of-the-art neuroimaging acquisition and analysis protocols; (3) Expand transdisciplinary regional neuroscience research using advanced neuroimaging tools to study disease mechanisms and treatments for neurodegeneration; (4) Support and collaborate with major national and international AD-related research consortia using neuroimaging and genetics methods; (5) Provide transdisciplinary educational opportunities in neuroimaging and genetics of AD and other degenerative disorders for basic and clinical scientists at all levels from undergraduates to post-doctoral fellows and faculty, as well as dissemination of neuroimaging results to the community. The NIC, working closely with the Clinical Core, will perform state-of- the-art multimodal MRI (Siemens Prisma 3T: high resolution structural, 3D pCASL perfusion, multiband resting- state and task-based fMRI, and hybrid diffusion and DTI optimized for structural and functional connectome analysis) on all eligible IADRC participants, as well as amyloid and/or tau PET on >200 IADRC participants. Participants in preclinical or early symptomatic phases (e.g., subjective cognitive decline or mild cognitive impairment), late-onset AD, and individuals from families with mutations causal for dementias will be prioritized. Imaging-pathologic correlation when available will improve the understanding of early structural, functional, and molecular changes observed in vivo and may help identify novel therapeutic targets. Cross- modality image analyses and results of imaging genetics studies with ADNI, DIAN, and others will contribute to advances in early detection, mechanistic understanding, and optimize imaging as a dynamic biomarker to study therapeutic effects. Acquiring standardized state-of-the-art MRI and PET data for use by many investigators will increase research productivity and facilitate quantitative analyses. Integration with other cores will allow the IADRC to expand on these analyses by relating imaging biomarkers to neuropsychological measures, neuropathologic samples, genetic and other –omics markers. The NIC will continue to foster and support advanced imaging research through local, regional, and national/international collaborations. The NIC will advance AD imaging research to meet the goal of NAPA for preventing and effectively treating AD by 2025.

项目摘要 – 神经影像核心 (NIC) IADRC 的 NIC 将作为老龄化和神经退行性疾病的区域和国家资源研究社区通过提供先进应用的访问和协作支持 NIC 在临床和转化研究方面的神经影像学的开发和应用取得了丰硕的成果。在神经影像和影像遗传学分析中实施尖端协议和技术，与 NIA 资助的项目（例如 ADNI、DIAN、ADGC 等）合作，并提供以下方面的培训：在此应用中，NIC 将向各个级别和学科的科学家提供神经影像和影像遗传学。追求以下具体目标：(1) 支持 IADRC、印第安纳大学老龄化研究中心资助的研究，以及目前采用先进神经影像学或可能受益于先进神经影像学的相关计划； (2) 提供 (3) 拓展跨学科使用先进的神经影像工具进行区域神经科学研究，以研究疾病机制和神经退行性疾病的治疗；（4）支持和与主要的国家和国际 AD 相关的合作使用神经影像学和遗传学方法的研究联盟；（5）提供跨学科教育； AD 和其他退行性疾病的神经影像学和遗传学基础和临床机会从本科生到博士后研究员和教师的各个级别的科学家，以及传播 NIC 将与临床核心密切合作，向社区提供神经影像结果。最先进的多模态 MRI（Siemens Prisma 3T：高分辨率结构、3D pCASL 灌注、多波段静息）基于状态和任务的 fMRI，以及针对结构和功能连接组优化的混合扩散和 DTI 对所有符合条件的 IADRC 参与者进行分析），以及对超过 200 名 IADRC 参与者进行淀粉样蛋白和/或 tau PET 分析。处于临床前或早期症状阶段的参与者（例如，主观认知能力下降或轻度认知能力下降）损伤）、迟发性 AD 以及来自携带导致痴呆症的突变的家庭的个体将优先考虑成像病理相关性（如果可用）将提高对早期结构、体内观察到的功能和分子变化可能有助于确定新的治疗靶点。 ADNI、DIAN 等的模态图像分析和成像遗传学研究结果将有助于在早期检测、机制理解和优化成像作为动态生物标志物方面取得的进展研究治疗效果。获取标准化的最先进的 MRI 和 PET 数据供许多人使用。研究人员将提高研究生产力并促进与其他核心的整合。将允许 IADRC 通过将成像生物标志物与神经心理学相关联来扩展这些分析 NIC 将继续培育和研究措施、神经病理样本、遗传和其他组学标记。通过地方、区域和国家/国际合作支持先进的影像研究。将推进AD影像学研究，以实现NAPA到2025年预防和有效治疗AD的目标。